Top

Published in:

Open Access 01-12-2016 | Research article

HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection

Authors: François M. J. Lamoury, Behzad Hajarizadeh, Elizabeth Keoshkerian, Jordan J. Feld, Janaki Amin, Suzy Teutsch, Gail V. Matthews, Margaret Hellard, Gregory J. Dore, Andrew R. Lloyd, Tanya L. Applegate, Jason Grebely, on behalf of the ATAHC Study Group

Published in: BMC Infectious Diseases | Issue 1/2016

Abstract

Background

Human immunodeficiency virus (HIV) infection leads to more rapid progression of hepatitis C virus (HCV)-related liver fibrosis, which could be linked to differences in the severity of liver inflammation among HIV/HCV co-infected individuals compared to HCV mono-infected individuals.

This study assessed the association of HIV co-infection with pro-inflammatory and pro-fibrogenic cytokines and chemokines during recent HCV infection.

Methods

Participants from the ATAHC study, a prospective cohort of recent HCV infection, with detectable HCV RNA at the time of acute HCV detection were included. Concentrations of 27 plasma cytokines and chemokines were measured by multiplex immunoassays and compared between those with, and without, HIV co-infection.

Results

Out of 117 individuals with recent HCV infection included in analysis, 73 had HCV mono-infection and 44 had HIV/HCV co-infection. Individuals with HIV/HCV co-infection had significantly higher mean levels of eotaxin (1.79 vs. 1.62 log pg/mL; P < 0.001), monocyte chemotactic protein 1 (MCP-1; 2.10 vs. 1.98 log pg/mL; P < 0.001), and interferon-gamma inducible protein-10 (IP-10; 3.11 vs. 2.98 log pg/mL; P = 0.013). Linear regression analyses adjusting for age, alanine transaminase (ALT), HCV RNA levels, and assay run, higher eotaxin levels were independently associated with HIV/HCV co-infection (adjusted β: 0.12; 95%CI: 0.01, 0.24; P = 0.039). Higher MCP-1 levels were also independently associated with HIV/HCV co-infection in adjusted analysis (adjusted β: 0.11; 95%CI: 0.03, 0.18; P = 0.009).

Conclusions

During recent HCV, those with HIV/HCV co-infection had a stronger pro-fibrogenic mediator profile compared to those with HCV mono-infection. These findings may provide a potential explanation for accelerated liver fibrosis in HIV/HCV co-infection.

Trial registration

Australian Trial in Acute Hepatitis C (ATAHC) study was registered with ClinicalTrials.gov registry on September 11, 2005. NCT00192569.

Available only for authorised users

Di Martino V, Rufat P, Boyer N, Renard P, Degos F, Martinot-Peignoux M, et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology. 2001;34(6):1193–9. doi:10.1053/jhep.2001.29201.CrossRefPubMed

Goedert JJ, Eyster ME, Lederman MM, Mandalaki T, De Moerloose P, White 2nd GC, et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood. 2002;100(5):1584–9.PubMed

Kirk GD, Mehta SH, Astemborski J, Galai N, Washington J, Higgins Y, et al. HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med. 2013;158(9):658–66. doi:10.7326/0003-4819-158-9-201305070-00604.CrossRefPubMedPubMedCentral

Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: A meta-analysis. AIDS. 2008;22(15):1979–91.CrossRefPubMed

Macías J, Berenguer J, Japón MA, Girón JA, Rivero A, López-Cortés LF, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology. 2009;50(4):1056–63. doi:10.1002/hep.23136.CrossRefPubMed

Lin W, Weinberg EM, Chung RT. Pathogenesis of Accelerated Fibrosis in HIV/HCV Co-infection. J Infect Dis. 2013;207 suppl 1:S13–8. doi:10.1093/infdis/jis926.CrossRefPubMedPubMedCentral

Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999;30(4):1054–8. doi:10.1002/hep.510300409.CrossRefPubMed

Monto A, Kakar S, Dove LM, Bostrom A, Miller EL, Wright TL. Contributions to hepatic fibrosis in HIV-HCV coinfected and HCV monoinfected patients. Am J Gastroenterol. 2006;101(7):1509–15. doi:10.1111/j.1572-0241.2006.00613.x.CrossRefPubMed

Kushner LE, Wendelboe AM, Lazzeroni LC, Chary A, Winters MA, Osinusi A, et al. Immune biomarker differences and changes comparing HCV mono-infected, HIV/HCV co-infected, and HCV spontaneously cleared patients. PLoS One. 2013;8(4):e60387. doi:10.1371/journal.pone.0060387.CrossRefPubMedPubMedCentral

10.

Zeremski M, Dimova RB, Makeyeva J, Sipley JD, Jacobson IM, Rennert H, et al. IL28B polymorphism, pretreatment CXCL10, and HCV RNA levels predict treatment response in racially diverse HIV/HCV coinfected and HCV monoinfected patients. J Acquir Immune Defic Syndr. 2013;63(1):9–16. doi:10.1097/QAI.0b013e31828323c1.CrossRefPubMed

11.

Kuntzen T, Tural C, Li B, Feldmann G, Kupfer B, Nischalke HD, et al. Intrahepatic mRNA expression in hepatitis C virus and HIV/hepatitis C virus co-infection: infiltrating cells, cytokines, and influence of HAART. AIDS. 2008;22(2):203–10. doi:10.1097/QAD.0b013e3282f3553b.CrossRefPubMed

12.

Grebely J, Feld JJ, Applegate T, Matthews GV, Hellard M, Sherker A, et al. Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology. 2013;57(6):2124–34. doi:10.1002/hep.26263.CrossRefPubMedPubMedCentral

13.

Dore GJ, Hellard M, Matthews GV, Grebely J, Haber PS, Petoumenos K, et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology. 2010;138(1):123–35. doi:10.1053/j.gastro.2009.09.019. e1-2.CrossRefPubMedPubMedCentral

14.

O’Connor KA, Holguin A, Hansen MK, Maier SF, Watkins LR. A method for measuring multiple cytokines from small samples. Brain Behav Immun. 2004;18(3):274–80. doi:10.1016/j.bbi.2003.09.009.CrossRefPubMed

15.

Heijmans-Antonissen C, Wesseldijk F, Munnikes RJ, Huygen FJ, van der Meijden P, Hop WC, et al. Multiplex bead array assay for detection of 25 soluble cytokines in blister fluid of patients with complex regional pain syndrome type 1. Mediat Inflamm. 2006;2006(1):28398. doi:10.1155/MI/2006/28398.

16.

Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, et al. Induction of a Striking Systemic Cytokine Cascade prior to Peak Viremia in Acute Human Immunodeficiency Virus Type 1 Infection, in Contrast to More Modest and Delayed Responses in Acute Hepatitis B and C Virus Infections. J Virol. 2009;83(8):3719–33. doi:10.1128/jvi.01844-08.CrossRefPubMedPubMedCentral

17.

Perneger TV. What’s wrong with Bonferroni adjustments. BMJ. 1998;316(7139):1236–8. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1112991/pdf/1236.pdf.

18.

Rothman KJ. No Adjustments Are Needed for Multiple Comparisons. Epidemiology. 1990;1(1):43–6.CrossRefPubMed

19.

Savitz DA, Olshan AF. Multiple Comparisons and Related Issues in the Interpretation of Epidemiologic Data. Am J Epidemiol. 1995;142(9):904–8.PubMed

20.

Thompson JR. Invited Commentary: Re: ‘Multiple Comparisons and Related Issues in the Interpretation of Epidemiologic Data”. Am J Epidemiol. 1998;147(9):801–6. doi:10.1093/oxfordjournals.aje.a009530.CrossRefPubMed

21.

Baeck C, Wehr A, Karlmark KR, Heymann F, Vucur M, Gassler N, et al. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut. 2012;61(3):416–26. doi:10.1136/gutjnl-2011-300304.CrossRefPubMed

22.

Fisher NC, Neil DA, Williams A, Adams DH. Serum concentrations and peripheral secretion of the beta chemokines monocyte chemoattractant protein 1 and macrophage inflammatory protein 1alpha in alcoholic liver disease. Gut. 1999;45(3):416–20.CrossRefPubMedPubMedCentral

23.

Weiss L, Si-Mohamed A, Giral P, Castiel P, Ledur A, Blondin C, et al. Plasma levels of monocyte chemoattractant protein-1 but not those of macrophage inhibitory protein-1alpha and RANTES correlate with virus load in human immunodeficiency virus infection. J Infect Dis. 1997;176(6):1621–4.CrossRefPubMed

24.

Tacke F. Functional role of intrahepatic monocyte subsets for the progression of liver inflammation and liver fibrosis in vivo. Fibrogenesis Tissue Repair. 2012;5 Suppl 1:S27.CrossRefPubMedPubMedCentral

25.

Seki E, de Minicis S, Inokuchi S, Taura K, Miyai K, van Rooijen N, et al. CCR2 promotes hepatic fibrosis in mice. Hepatology. 2009;50(1):185–97. doi:10.1002/hep.22952.CrossRefPubMedPubMedCentral

26.

Marra F, DeFranco R, Grappone C, Milani S, Pastacaldi S, Pinzani M, et al. Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am J Pathol. 1998;152(2):423–30.PubMedPubMedCentral

27.

Zimmermann HW, Seidler S, Nattermann J, Gassler N, Hellerbrand C, Zernecke A, et al. Functional Contribution of Elevated Circulating and Hepatic Non-Classical CD14 < sup > +</sup > CD16 < sup > +</sup > Monocytes to Inflammation and Human Liver Fibrosis. PLoS ONE. 2010;5(6):e11049. doi:10.1371/journal.pone.0011049.CrossRefPubMedPubMedCentral

28.

Marsillach J, Bertran N, Camps J, Ferré N, Riu F, Tous M, et al. The role of circulating monocyte chemoattractant protein-1 as a marker of hepatic inflammation in patients with chronic liver disease. Clin Biochem. 2005;38(12):1138–40. doi: http://dx.doi.org/10.1016/j.clinbiochem.2005.09.006.CrossRefPubMed

29.

Mühlbauer M, Bosserhoff AK, Hartmann A, Thasler WE, Weiss TS, Herfarth H, et al. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology. 2003;125(4):1085–93. doi: http://dx.doi.org/10.1016/S0016-5085(03)01213-7.CrossRefPubMed

30.

Farci P, Wollenberg K, Diaz G, Engle RE, Lai ME, Klenerman P, et al. Profibrogenic chemokines and viral evolution predict rapid progression of hepatitis C to cirrhosis. Proc Natl Acad Sci. 2012;109(36):14562–7. doi:10.1073/pnas.1210592109.CrossRefPubMedPubMedCentral

31.

Tuyama AC, Hong F, Saiman Y, Wang C, Ozkok D, Mosoian A, et al. Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: Implications for the pathogenesis of HIV/hepatitis C virus–induced liver fibrosis. Hepatology. 2010;52(2):612–22. doi:10.1002/hep.23679.CrossRefPubMedPubMedCentral

32.

Mitchell C, Couton D, Couty J-P, Anson M, Crain A-M, Bizet V, et al. Dual Role of CCR2 in the Constitution and the Resolution of Liver Fibrosis in Mice. Am J Pathol. 2009;174(5):1766–75. doi: http://dx.doi.org/10.2353/ajpath.2009.080632.CrossRefPubMedPubMedCentral

33.

Parker R, Walters M, Ertl L, Ebsworth K, Tan J, McMahon J, et al. Therapeutic use of a clinical stage CCR2 inhibitor, CCX872, in obesity-associated steatohepatitis. Lancet. 2014;383:S78. doi:10.1016/S0140-6736(14)60341-X [abstract].CrossRef

34.

Gathe J, Cade J, De Jesus E, et al. Week-24 primary analysis of cenicriviroc vs efavirenz, in combination with emtricitabine/tenofovir, in treatment-naive HIV-1+ adults with CCR5-tropic virus. Atlanta: The 20th Conference on Retroviruses and Opportunistic Infections; 2013. 3–6 March. p. [abstract 106LB].

35.

Feinberg J, Thompson M, Cade J, et al. Final week 48 analysis of cenicriviroc compared to efavirenz in combination with emtricitabine/tenofovir in treatment-naïve HIV-1-infected adults with CCR5-tropic virus. Brussels: The 14th EACS; 2013. 16–19 October. p. [abstract PS4/1].

36.

Hong F, Chou H, Friedman SL. Significant anti-fibrotic activity of cenicriviroc, a dual CCR2/CCR5 antagonist in a rat model of thioacetamide-induced liver fibrosis and cirrhosis. Hepatology. 2013;58(6):1381A [abstract].

37.

Broide D, Sriramarao P. Eosinophil trafficking to sites of allergic inflammation. Immunol Rev. 2001;179(1):163–72. doi:10.1034/j.1600-065X.2001.790116.x.CrossRefPubMed

38.

Lampinen M, Carlson M, Håkansson LD, Venge P. Cytokine-regulated accumulation of eosinophils in inflammatory disease. Allergy. 2004;59(8):793–805. doi:10.1111/j.1398-9995.2004.00469.x.CrossRefPubMed

39.

Pham B-N, Bernuau J, Durand F, Sauvanet A, Degott C, Prin L, et al. Eotaxin expression and eosinophil infiltrate in the liver of patients with drug-induced liver disease. J Hepatol. 2001;34(4):537–47. doi:http://dx.doi.org/10.1016/S0168-8278(00)00057-X.CrossRefPubMed

40.

Yoneda S, Umemura T, Joshita S, Ichijo T, Matsumoto A, Yoshizawa K, et al. Serum chemokine levels are associated with the outcome of pegylated interferon and ribavirin therapy in patients with chronic hepatitis C. Hepatol Res. 2011;41(6):587–93. doi:10.1111/j.1872-034X.2011.00802.x.CrossRefPubMed

41.

Osburn WO, Levine JS, Chattergoon MA, Thomas DL, Cox AL. Anti-inflammatory cytokines, pro-fibrogenic chemokines and persistence of acute HCV infection. J Viral Hepat. 2013;20(6):404–13. doi:10.1111/jvh.12052.CrossRefPubMed

42.

Tacke F, Trautwein C, Yagmur E, Hellerbrand C, Wiest R, Brenner DA, et al. Up-regulated eotaxin plasma levels in chronic liver disease patients indicate hepatic inflammation, advanced fibrosis and adverse clinical course. J Gastroenterol Hepatol. 2007;22(8):1256–64. doi:10.1111/j.1440-1746.2006.04621.x.CrossRefPubMed

Title: HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection
Authors: François M. J. Lamoury
Behzad Hajarizadeh
Elizabeth Keoshkerian
Jordan J. Feld
Janaki Amin
Suzy Teutsch
Gail V. Matthews
Margaret Hellard
Gregory J. Dore
Andrew R. Lloyd
Tanya L. Applegate
Jason Grebely
on behalf of the ATAHC Study Group
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: BMC Infectious Diseases / Issue 1/2016
Electronic ISSN: 1471-2334
DOI: https://doi.org/10.1186/s12879-016-1567-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection

Abstract

Background

Methods

Results

Conclusions

Trial registration

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2016

Influence of social contact patterns and demographic factors on influenza simulation results

Carbapenem-Resistant Klebsiella pneumoniae influences the outcome of early infections in liver transplant recipients

Performance of Syphilis Sentinel Surveillance in the context of endemic Treponematoses: experience from Ghana

Clinical impact of methicillin-resistant staphylococcus aureus on bacterial pneumonia: cultivation and 16S ribosomal RNA gene analysis of bronchoalveolar lavage fluid

A case report of a cystic fibrosis patient with repeated isolation of Trichosporon mycotoxinivorans identified by a novel short-extraction method

Title: role of matrix metalloproteinase −9 in progression of tuberculous meningitis: a pilot study in patients at different stages of the disease

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page